Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01355471 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Phase 3 study, sponsored by Galderma R&D.

Completed
Registry status
Phase 3
Development phase
293
Enrollment target

NCT01355471: Completed Phase 3 study, sponsored by Galderma R&D.

NCT01355471 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 293 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01355471, a Phase 3 study, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 3
Development phase
293 participants
Enrollment target

Study Summary

This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

Primary Outcome

Composite Success is defined as 2-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

Interventions

  • DRUG Placebo
  • DRUG CD07805/47 Gel

Trial Details

FieldValue
Enrollment Target 293 participants
Start Date 2011-05
Est. Completion 2012-01
Phase Phase 3
Galderma R&D

158 total trials

What the finished NCT01355471 record still lists

NCT01355471 is an interventional study that assigns participants to a tested intervention. The registered 293 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01355471 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01355471 about?

NCT01355471 is a clinical study titled "Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of fac...

What is the current status of trial NCT01355471?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 293 participants. The study started on 2011-05. Estimated completion is 2012-01.

What interventions are being tested in trial NCT01355471?

The interventions under investigation include: Placebo (DRUG), CD07805/47 Gel (DRUG).

Who is sponsoring clinical trial NCT01355471?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01355471's enrollment target sits among peer trials

293 1166th of 2000 higher than 835 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05775159 · 294 participants · Phase 2

    Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

  • NCT06262113 · 294 participants · NA

    A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1

  • NCT06338865 · 294 participants · NA

    Short Title: Standard vs. Lower Pressure Pneumoperitoneum

  • NCT06395467 · 294 participants · NA

    Integrated Treatment for Enhancing Growth in Recovery During Adolescence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01355471, the US trial registry maintained by the National Library of Medicine. NCT01355471 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.